LOS ANGELES--(BUSINESS WIRE)--Feb. 23, 2006--At their 2005 Annual Meeting held in Los Angeles on January 31, 2006, the shareholders of CytoDyn, Inc. (OTCBB:CYDY) overwhelmingly approved management’s recommendations. This included reelecting scientist Allen D. Allen as Chairman of the Board. Mr. Allen invented the Company’s targeted immune therapy for treating HIV/AIDS and gave it the trade name Cytolin(R). To date, Cytolin(R) has been studied in human subjects through Phase I(b)/II(a) with encouraging results. Before joining the private sector, Mr. Allen was engaged in AIDS research and education with grants from OrthoBiotech, a division of Johnson and Johnson (NYSE:JNJ), and other major pharmaceutical companies.
